Camille D. Samuels
Director/Board Member chez UNITY BIOTECHNOLOGY, INC.
Fortune : 1 666 $ au 31/03/2024
Profil
Camille (Cami) focuses on healthcare with an emphasis on biotech, medical devices, and consumer health.
Temperamentally an early-stage investor and company helper, Cami currently serves on the board of Cavalry, Iris, Mahzi, Ocelot, Unity (UBX), and is a board observer at Interdict.
She previously served on the board of several exited Venrock portfolio companies, including Corvidia (sold to Novo), RegenXBio (RGNX), and Spirox (owned by Stryker).
Prior to Venrock, Cami was a Managing Director at Versant Ventures where she served on the board (or as a board observer) at many companies including Genomic Health (GHDX/sold to Exact), Jazz (JAZZ), Kythera (KYTH/sold to Allergan), and Novacardia (sold to Merck).
During her early career, Cami worked in corporate development at Genzyme, Millennium Predictive Medicine, and Tularik, and she was a management consultant at LEK.
Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School (HBS), where she graduated as a Baker Scholar.
She is a Henry Crown Fellow, serves on the Investment Advisory Committee of Mission BioCapital (MBC), and serves on the HBS Global Advisory Board.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 23/06/2023 | 1 016 ( 0,01% ) | 1 666 $ | 31/03/2024 |
Postes actifs de Camille D. Samuels
| Sociétés | Poste | Début |
|---|---|---|
| UNITY BIOTECHNOLOGY, INC. | Director/Board Member | 01/03/2015 |
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Private Equity Investor | 01/05/2014 |
Mahzi Therapeutics, Inc.
 Mahzi Therapeutics, Inc. BiotechnologyHealth Technology Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation. | Director/Board Member | - |
Mission Bay Capital Management, Inc.
 Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | Consultant / Advisor | - |
Ocelot Bio, Inc.
 Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | Director/Board Member | - |
Biolux Research Holdings, Inc.
 Biolux Research Holdings, Inc. Medical/Nursing ServicesHealth Services Biolux Research Holdings, Inc. engages in healthcare services. The company is headquartered in Pleasanton, CA. | Director/Board Member | - |
| Muse Therapeutics, Inc. | Director/Board Member | 22/07/2009 |
HBS Global Properties LLC
 HBS Global Properties LLC Real Estate DevelopmentFinance HBS Global Properties LLC is an American company that specializes in the development, brokerage, and management of residential and commercial properties. The private company is based in New York. | Consultant / Advisor | - |
Anciens postes connus de Camille D. Samuels
| Sociétés | Poste | Fin |
|---|---|---|
| REGENXBIO INC. | Director/Board Member | 05/08/2016 |
| ░░░░░░░ ░░░░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Camille D. Samuels
| Duke University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| STANDARD BIOTOOLS INC. | Health Technology |
| REGENXBIO INC. | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| Entreprise privées | 25 |
|---|---|
Venrock Associates
Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Finance |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Syrrx, Inc.
 Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Genomic Health, Inc.
 Genomic Health, Inc. Medical SpecialtiesHealth Technology Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA. | Health Technology |
NovaCardia, Inc.
 NovaCardia, Inc. Pharmaceuticals: MajorHealth Technology NovaCardia, Inc. develops drugs to treat cardiovascular diseases. The company provides treatment for the patients by developing and commercializing clinical stage drug diseases. It also develops small molecule drugs. the company was founded in November, 2001 by Eckard Weber & Howard C. Dittrich and is headquartered in San Diego, CA. | Health Technology |
ParAllele BioScience, Inc.
 ParAllele BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA. | Commercial Services |
Kythera Biopharmaceuticals LLC
 Kythera Biopharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Kythera Biopharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel prescription products for the aesthetic medicine market. The company was founded by Jay Edward Birnbaum, Amit D. Munshi, Nathaniel Eames David, and Keith R. Leonard, Jr. on June 3, 2004 and is headquartered in Westlake, CA. | Health Technology |
APT Pharmaceuticals, Inc.
 APT Pharmaceuticals, Inc. BiotechnologyHealth Technology APT Pharmaceuticals, Inc. operated as a drug development company. The company was founded on December 15, 1999 and was headquartered in Burlingame, CA. | Health Technology |
Semprae Laboratories, Inc.
 Semprae Laboratories, Inc. Medical/Nursing ServicesHealth Services Semprae Laboratories, Inc. provides consumer products for female sexual health. The company was founded by Rachel Braun Scherl and Mary Wallace Jaensch in 2008 and is headquartered in San Diego, CA. | Health Services |
Spirox, Inc.
 Spirox, Inc. Medical SpecialtiesHealth Technology Spirox, Inc. develops medical devices. Its product LATERA Absorbable Nasal Implant is designed to address causes of nasal obstruction today, nasal valve collapse caused by weakened lateral wall cartilage. The company was founded by Donald Albert Gonzales and Iyad Saidi on November 3, 2011 and is headquartered in Menlo Park, CA. | Health Technology |
Carmenta Bioscience, Inc.
 Carmenta Bioscience, Inc. Medical SpecialtiesHealth Technology Carmenta Bioscience, Inc. provides biotechnology services. It offers technology that medical need in maternal and fetal health. The company was founded by Matthew Cooper, Atul J. Butte, and Bruce Ling in 2012 and is headquartered Palo Alto, CA. | Health Technology |
The Lek/Alcar Consulting Group, Inc.
 The Lek/Alcar Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Lek/Alcar Consulting Group, Inc. provides business strategy consulting services. It offers strategy, finance, marketing and sales, operations, and transaction services including business unit strategy, brand management, pricing, alliances and joint ventures, product development, corporate transformation, and operations design. It serves the defense, energy, health, building and construction, aerospace, media, retail, and telecommunications industries. The company was founded by Andrew Kutter in 1983 and is headquartered in Boston, MA. | Commercial Services |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Anza Therapeutics, Inc.
 Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA. | Health Technology |
Transcept Pharma, Inc.
 Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
| Muse Therapeutics, Inc. | |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | Finance |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Health Technology |
Biolux Research Holdings, Inc.
Biolux Research Holdings, Inc. Medical/Nursing ServicesHealth Services Biolux Research Holdings, Inc. engages in healthcare services. The company is headquartered in Pleasanton, CA. | Health Services |
HBS Global Properties LLC
HBS Global Properties LLC Real Estate DevelopmentFinance HBS Global Properties LLC is an American company that specializes in the development, brokerage, and management of residential and commercial properties. The private company is based in New York. | Finance |
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | Health Technology |
Mahzi Therapeutics, Inc.
Mahzi Therapeutics, Inc. BiotechnologyHealth Technology Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation. | Health Technology |
